evorpacept
evorpacept: developed by 1 company · 4 clinical trials tracked.
evorpacept evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could evorpacept → ALXO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) Breast Cancer, Metastatic | Phase 2 |
Clinical Trials (4)
Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Primary endpoint: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Primary endpoint: Objective Response Rate (ORR)
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Primary endpoint: Incidence of dose-limiting toxicities (DLTs; Part 1)
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Primary endpoint: Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
Frequently asked questions
Who is developing evorpacept?
evorpacept is being developed by ALX ONCOLOGY HOLDINGS INC.
How many clinical trials involve evorpacept?
BioSniper tracks 4 clinical trials involving evorpacept.